{"DataElement":{"publicId":"5434513","version":"1","preferredName":"Retinoid X Receptors Expression Type","preferredDefinition":"Information related to a type of measurement of protein expression in IHC experiments, human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways.","longName":"RXR_EXPR_TYPE","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"5434512","version":"1","preferredName":"Retinoid X Receptors Expression","preferredDefinition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways. RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)_A combination of symbols that represents a value.","longName":"RXR_EXPR","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"3269818","version":"1","preferredName":"Retinoid X Receptors","preferredDefinition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways. RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)","longName":"C0140283","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoid X Receptors","conceptCode":"C0140283","definition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways. RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC46B303-421E-EC24-E040-BB89AD431A2A","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2928439","version":"1","preferredName":"Expression","preferredDefinition":"A combination of symbols that represents a value.","longName":"C80488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Expression","conceptCode":"C80488","definition":"A combination of symbols that represents a value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7086B234-A550-F6FD-E040-BB89AD432532","latestVersionIndicator":"Yes","beginDate":"2009-08-07","endDate":null,"createdBy":"UMLLOADER_ISO","dateCreated":"2009-08-07","modifiedBy":"ONEDATA","dateModified":"2009-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B383EC8-857C-FA0D-E050-BB89AD433723","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-29","modifiedBy":"MORENOC","dateModified":"2017-11-29","changeDescription":"11/29/2017: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5434473","version":"1","preferredName":"Retinoid X Receptor Expression Type","preferredDefinition":"A type of measurement of protein expression in IHC experiments.  Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways.","longName":"RXR_EXPR_TYPE","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"High","valueDescription":"High","ValueMeaning":{"publicId":"4382322","version":"1","preferredName":"High","longName":"4382322","preferredDefinition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDB15654-DC5E-A91B-E040-BB89AD43310F","latestVersionIndicator":"Yes","beginDate":"2014-07-08","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-07-08","modifiedBy":"COLBERTM","dateModified":"2022-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B3943B5-9AED-73F8-E050-BB89AD4369A8","beginDate":"2006-11-13","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-29","modifiedBy":"ONEDATA","dateModified":"2016-08-29","deletedIndicator":"No"},{"value":"Low","valueDescription":"Low","ValueMeaning":{"publicId":"5434474","version":"1","preferredName":"Low","longName":"5434474","preferredDefinition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3943B5-9AF7-73F8-E050-BB89AD4369A8","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-29","modifiedBy":"COLBERTM","dateModified":"2022-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B3943B5-9B10-73F8-E050-BB89AD4369A8","beginDate":"2006-11-13","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-29","modifiedBy":"ONEDATA","dateModified":"2016-08-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5434472","version":"1","preferredName":"Retinoid X Receptor Expression Type","preferredDefinition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways.  RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI):A combination of symbols that represents a value.:Something distinguishable as an identifiable class based on common qualities.","longName":"C17534:C80488:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoid X Receptor","conceptCode":"C17534","definition":"Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways.  RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Expression","conceptCode":"C80488","definition":"A combination of symbols that represents a value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3943B5-9AC9-73F8-E050-BB89AD4369A8","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-29","modifiedBy":"ONEDATA","dateModified":"2016-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3943B5-9ADA-73F8-E050-BB89AD4369A8","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-29","modifiedBy":"MORENOC","dateModified":"2017-11-29","changeDescription":"11/29/2017: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Tumor RXR expression","type":"Preferred Question Text","description":"Tumor RXR expression","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B398C55-8BC6-F057-E050-BB89AD436019","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-29","modifiedBy":"MORENOC","dateModified":"2017-11-29","changeDescription":"11/29/2017: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}